InspireMD has expanded its MGuard production facilities to meet the steady increase in demand of mesh technology produced in MGuard mesh protected coronary stent system.
The driving forces behind the accelerating demand for MGuard include the recommendation of the European Society of Cardiology (ESC) mesh-based protection to be considered for percutaneous coronary interventions (PCI) of highly thrombotic or saphenous vein graft (SVG) lesions.
Currently, this type of approved mesh technology is exclusively produced by InspireMD in its MGuard mesh protected coronary stent system.
The CE mark approved MGuard presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients.
The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent.
InspireMD CEO Ofir Paz said one of the main success factors of their business is their ability to produce and deliver our high quality products to match demand.
"We are very pleased to see that our MGuard solution is becoming widely accepted as the preferred alternative for thrombus management in heart attack patients. The current expansion is the beginning of a major expansion in our production designed to meet the continued upward demand for MGuard solutions worldwide," Paz said.